The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The transaction is anticipated to close in the first quarter of 2022
The first clinical trial is expected to commence in early 2022 both in Europe and the US
More than 90,000 patients utilise the services daily
The state-of-the-art facility provides a pathway from development to large-scale biologics production
Subscribe To Our Newsletter & Stay Updated
